Benign Prostatic Hyperplasia Clinical Trial
— EPUREOfficial title:
Evaluation of Procedure Tuna Within the Framework of a Hospitalization of Short Duration
Verified date | April 2009 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The TUNA is a known and already old technique. There exists, in the literature, a certain number of studies showing the long-term effectiveness (5 years), evaluated on the IPS and the flow mictional.This effectiveness is slightly lower than that of the endoscopic resection of prostate. This technique does not present the disadvantages of the surgery prostate sufferer on ejaculation. Moreover, it can be carried out in short hospitalization or ambulatory as it is the case in particular in the States Unis. The aim of the study which will be led by the AP-HP will be thus to test the feasibility of the TUNA during a hospitalization of less 24 hours.
Status | Completed |
Enrollment | 53 |
Est. completion date | March 2009 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years to 85 Years |
Eligibility |
Inclusion Criteria: 1. Man whose age is superior or egal to 45 and inferior or egal to 85 years 2. Patient presenting an anaesthetic risk of ASA 1 at 3 3. Patient accepting the protocol, in particular the return to residence with a sounder 4. Patient presenting a TUBA related to a HBP and lasting since more than 3 months 1. with a gene score higher superior or egal to 3 2. with a score IPS superior to 8 5. Patient presenting a prostate whose estimated weight is inferior or egal to 80g, without median lobe prevailing and whose transverse width lies between 34 and 80 mm. 6. Patient having a residue post mictional lower than 200cc. 7. Patient presenting a normal renal function 8. Patient having a result PSA £ 4 ng/ml, or negative biopsies if PSA > 4 and < 10 ng/ml 9. Patient having given his free and in writing lit assent 10. Patient affiliated to the Social security or an assimilated mode 11. Patient having stopped his treatment by 5 alpha reductase since at least a month (1) Exclusion Criteria: 1. Patient presenting a urinary infection 2. Patient presenting an acute retention of urine 3. Patient presenting a neurological bladder and/or of an anomaly of the sphincter 4. Patient currently under anticoagulant treatment. 5. Patient currently under anti-inflammatory treatment. 6. Patient presenting an affection or a confirmed or suspected malignant tumour of the prostates or vegie. 7. Patient presenting an antecedent of surgery prostatic 8. Patient presenting of the biopsies prostate sufferers carried out less than 4 months before procedure TUNA 9. Patient introducing of the antecedents of vesical lithiasis, haematuria important, contracting of the urethra, stenosis of the vesical collar, pathologies of the bladder or sweetened diabetes affecting vesical operation, 10. Patient presenting a prosthesis in the zone being able to be affected by the procedure 11. Patient presenting a desire of fertility 12. Patient presenting an anorectal pathology 13. Patient presenting an allergy to the anaesthesia locale 14. Patient whose follow-up seems incompatible with the needs for the study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hôpital TENON - Service d'Urologie | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Left the hospital | the evening of the intervention | No | |
Primary | Not hospitalized for a complication related to the intervention | in the month following the intervention | No | |
Secondary | Evaluation of the satisfaction of the intervention for the patient | at 1 month | No | |
Secondary | Evaluation for the micturition of the following parameters | at 1 month | No | |
Secondary | Evaluation of the appeared minor complications | at 1 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT04853914 -
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
|
N/A |